Don't eat me/eat me signals as a novel strategy in cancer immunotherapy
Cancer stands as one of the prominent global causes of death, with its incidence burden continuously increasing, leading to a substantial rise in mortality rates. Cancer treatment has seen the development of various strategies, each carrying its drawbacks that can negatively impact the quality of li...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-10-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023077150 |
| _version_ | 1827780283896692736 |
|---|---|
| author | Amirreza Khalaji Fatereh Baharlouei Yancheshmeh Fatemeh Farham Arya Khorram Shiva Sheshbolouki Maryam Zokaei Fatemeh Vatankhah Mehdi Soleymani-Goloujeh |
| author_facet | Amirreza Khalaji Fatereh Baharlouei Yancheshmeh Fatemeh Farham Arya Khorram Shiva Sheshbolouki Maryam Zokaei Fatemeh Vatankhah Mehdi Soleymani-Goloujeh |
| author_sort | Amirreza Khalaji |
| collection | DOAJ |
| description | Cancer stands as one of the prominent global causes of death, with its incidence burden continuously increasing, leading to a substantial rise in mortality rates. Cancer treatment has seen the development of various strategies, each carrying its drawbacks that can negatively impact the quality of life for cancer patients. The challenge remains significant within the medical field to establish a definitive cancer treatment that minimizes complications and limitations.In the forthcoming years, exploring new strategies to surmount the failures in cancer treatment appears to be an unavoidable pursuit. Among these strategies, immunology-based ones hold substantial promise in combatting cancer and immune-related disorders. A particular subset of this approach identifies ''eat me'' and ''Don't eat me'' signals in cancer cells, contrasting them with their counterparts in non-cancerous cells. This distinction could potentially mark a significant breakthrough in treating diverse cancers. By delving into signal transduction and engineering novel technologies that utilize distinct ''eat me'' and ''Don't eat me'' signals, a valuable avenue may emerge for advancing cancer treatment methodologies.Macrophages, functioning as vital components of the immune system, regulate metabolic equilibrium, manage inflammatory disorders, oversee fibrosis, and aid in the repair of injuries. However, in the context of tumor cells, the overexpression of ''Don't eat me'' signals like CD47, PD-L1, and beta-2 microglobulin (B2M), an anti-phagocytic subunit of the primary histocompatibility complex class I, enables these cells to evade macrophages and proliferate uncontrollably. Conversely, the presentation of an ''eat me'' signal, such as Phosphatidylserine (PS), along with alterations in charge and glycosylation patterns on the cellular surface, modifications in intercellular adhesion molecule-1 (ICAM-1) epitopes, and the exposure of Calreticulin and PS on the outer layer of the plasma membrane represent universally observed changes on the surface of apoptotic cells, preventing phagocytosis from causing harm to adjacent non-tumoral cells.The current review provides insight into how signaling pathways and immune cells either stimulate or obstruct these signals, aiming to address challenges that may arise in future immunotherapy research. A potential solution lies in combination therapies targeting the ''eat me'' and ''Don't eat me'' signals in conjunction with other targeted therapeutic approaches. This innovative strategy holds promise as a novel avenue for the future treatment of cancer. |
| first_indexed | 2024-03-11T15:03:28Z |
| format | Article |
| id | doaj.art-26b783f136f747239c2dab169bf9233f |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-03-11T15:03:28Z |
| publishDate | 2023-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-26b783f136f747239c2dab169bf9233f2023-10-30T06:06:23ZengElsevierHeliyon2405-84402023-10-01910e20507Don't eat me/eat me signals as a novel strategy in cancer immunotherapyAmirreza Khalaji0Fatereh Baharlouei Yancheshmeh1Fatemeh Farham2Arya Khorram3Shiva Sheshbolouki4Maryam Zokaei5Fatemeh Vatankhah6Mehdi Soleymani-Goloujeh7Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, IranCardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IranFaculty of Medicine, Tehran University of Medical Sciences, Tehran, IranDepartment of Laboratory Sciences, School of Allied Medical Sciences, Alborz University of Medical Sciences, Karaj, IranFaculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, IranDepartment of Food Science and Technology, Faculty of Nutrition Science, Food Science and Technology/National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Veterinary Medicine, Beyza Branch, Islamic Azad University, Beyza, IranStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, IranDepartment of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran; Corresponding author.Cancer stands as one of the prominent global causes of death, with its incidence burden continuously increasing, leading to a substantial rise in mortality rates. Cancer treatment has seen the development of various strategies, each carrying its drawbacks that can negatively impact the quality of life for cancer patients. The challenge remains significant within the medical field to establish a definitive cancer treatment that minimizes complications and limitations.In the forthcoming years, exploring new strategies to surmount the failures in cancer treatment appears to be an unavoidable pursuit. Among these strategies, immunology-based ones hold substantial promise in combatting cancer and immune-related disorders. A particular subset of this approach identifies ''eat me'' and ''Don't eat me'' signals in cancer cells, contrasting them with their counterparts in non-cancerous cells. This distinction could potentially mark a significant breakthrough in treating diverse cancers. By delving into signal transduction and engineering novel technologies that utilize distinct ''eat me'' and ''Don't eat me'' signals, a valuable avenue may emerge for advancing cancer treatment methodologies.Macrophages, functioning as vital components of the immune system, regulate metabolic equilibrium, manage inflammatory disorders, oversee fibrosis, and aid in the repair of injuries. However, in the context of tumor cells, the overexpression of ''Don't eat me'' signals like CD47, PD-L1, and beta-2 microglobulin (B2M), an anti-phagocytic subunit of the primary histocompatibility complex class I, enables these cells to evade macrophages and proliferate uncontrollably. Conversely, the presentation of an ''eat me'' signal, such as Phosphatidylserine (PS), along with alterations in charge and glycosylation patterns on the cellular surface, modifications in intercellular adhesion molecule-1 (ICAM-1) epitopes, and the exposure of Calreticulin and PS on the outer layer of the plasma membrane represent universally observed changes on the surface of apoptotic cells, preventing phagocytosis from causing harm to adjacent non-tumoral cells.The current review provides insight into how signaling pathways and immune cells either stimulate or obstruct these signals, aiming to address challenges that may arise in future immunotherapy research. A potential solution lies in combination therapies targeting the ''eat me'' and ''Don't eat me'' signals in conjunction with other targeted therapeutic approaches. This innovative strategy holds promise as a novel avenue for the future treatment of cancer.http://www.sciencedirect.com/science/article/pii/S2405844023077150CancerDon't eat me signalEat me signalImmunotherapyPhagocytosis |
| spellingShingle | Amirreza Khalaji Fatereh Baharlouei Yancheshmeh Fatemeh Farham Arya Khorram Shiva Sheshbolouki Maryam Zokaei Fatemeh Vatankhah Mehdi Soleymani-Goloujeh Don't eat me/eat me signals as a novel strategy in cancer immunotherapy Heliyon Cancer Don't eat me signal Eat me signal Immunotherapy Phagocytosis |
| title | Don't eat me/eat me signals as a novel strategy in cancer immunotherapy |
| title_full | Don't eat me/eat me signals as a novel strategy in cancer immunotherapy |
| title_fullStr | Don't eat me/eat me signals as a novel strategy in cancer immunotherapy |
| title_full_unstemmed | Don't eat me/eat me signals as a novel strategy in cancer immunotherapy |
| title_short | Don't eat me/eat me signals as a novel strategy in cancer immunotherapy |
| title_sort | don t eat me eat me signals as a novel strategy in cancer immunotherapy |
| topic | Cancer Don't eat me signal Eat me signal Immunotherapy Phagocytosis |
| url | http://www.sciencedirect.com/science/article/pii/S2405844023077150 |
| work_keys_str_mv | AT amirrezakhalaji donteatmeeatmesignalsasanovelstrategyincancerimmunotherapy AT faterehbaharloueiyancheshmeh donteatmeeatmesignalsasanovelstrategyincancerimmunotherapy AT fatemehfarham donteatmeeatmesignalsasanovelstrategyincancerimmunotherapy AT aryakhorram donteatmeeatmesignalsasanovelstrategyincancerimmunotherapy AT shivasheshbolouki donteatmeeatmesignalsasanovelstrategyincancerimmunotherapy AT maryamzokaei donteatmeeatmesignalsasanovelstrategyincancerimmunotherapy AT fatemehvatankhah donteatmeeatmesignalsasanovelstrategyincancerimmunotherapy AT mehdisoleymanigoloujeh donteatmeeatmesignalsasanovelstrategyincancerimmunotherapy |